Waldenström’s macroglobulinemia: Report of two cases
Main Article Content
Abstract
Waldenstr๖m’s macroglobulinemia (WM) is a clonal neoplastic disease of the lymphoplasmacytic cell. The diagnostic criteria consist of lymphoplasmacytic cells more than 20 % in the bone marrow and monoclonal gammopathyIgM> 3 g%. It is a very rare disease of the senior age group worldwide as well as in Thailand. And herein, we reported two additional Thai patients. Both were males, ages were 58 and 82 years. Both had no complaint except for fatigue due to anemia. Their physical examination revealed no lymphadenopathy, no hepatosplenomegaly. Their blood tests were: Hb 7.7 and 6.6 g%, serum globulin 8.2 and 7.4 g%. With theimmunofixation method, themonoclonal gammopathyIgM, kappa type in the first and lambda type in the second case were demonstrated. The lymphoplasmacytic cells more than 20 % were found in the bone marrow both. No lytic lesion was seen in the bone survey. They were diagnosed as WM. Because of anemia, they were treated with oral cyclophosphamide on alternate day, besides blood transfusion. They could survive more than 2 years after the diagnosis while the anemia was gradually improved during the follow-up period. Other differential diagnosis of our cases was multiple myeloma or MM, IgM monoclonal gammopathy type because of the kidney impairment. Due to lack of the lytic bone lesion that was the important characteristic of MM, it was hardly possible to diagnose MM.
ผู้ป่วย WM ของเราทั้งสองราย นอกจากจะมีภาวะโลหิตจางแล้วมีเงื่อนงำเดียวที่พอช่วยให้นึกถึงโรคนี้ได้ คือการที่ระดับ globulin ในเลือดสูงขึ้นอย่างชัดเจน Both WM patients may result in only anemic symptomas in our cases, no organomegaly, its definite diagnosis could be delayedor even hardly possible if the clinician did not have adequate realization.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009; 23: 3-9.
García-Sanz R, Montoto S, Torrequebrada A, de Coca AG, Petit J, Sureda A, et al. Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases. Br J Haematol 2001; 115: 575-82.
Herrinton LJ, Weiss NS. Incidence of Waldenström’s macroglobulinemia. Blood 1993; 82: 3148-50.
Phekoo KJ, Jack RH, Davies E, M ller H, Schey SA; South Thames Haematology Specialist Committee. The incidence and survival of Waldenström’s Macroglobulinaemia in South East England. Leuk Res 2008; 32: 55-9.
Iwanaga M, Chiang CJ, Soda M, Lai MS, Yang YW, Miyazaki Y, et al. Incidence of lymphoplasmacytic lymphoma/Waldenström’s macroglobulinaemia in Japan and Taiwan population-based cancer registries, 1996-2003. Int J Cancer 2014; 134: 174-80.
RAMATHIBODI CANCER REPORT 2011, Faculty of Medicine, Ramathibodi Hospital, Mahidol University
วิชัย ประยูรวิวัฒน์. Waldenstrom’s macroglobulinemia. วารสารโลหิตวิทยาและเวชศาสตร์บริการโลหิต 2543; 10:147-151.
Schuster SR, Rajkumar SV, Dispenzieri A, Morice W, Aspitia AM, Ansell S, et al. IgM multiple myeloma: disease definition, prognosis and differentiation from Waldenstrom’s macroglobulinemia. Am J Hematol 2010; 85: 853-5.
Bhatt VR, Murukutla S, Naqi M, Pant S, Kedia S, Terjanian T. IgM myeloma or Waldenstrom’s macroglobulinemiai is the big question? Maedica (Buchar) 2014; 9: 72-5.
Jondeau K, Alterescu R, Franc B, Davi F, Massé JM, Boukour S, et al. Unusual evolution of Waldenström’s macroglobulinemia into osteolytic myeloma. Eur J Haematol 2006; 77: 74-9.
Chen CI. Treatment for Waldenstrom’s macroglobulinemia. Ann Oncol 2004; 15: 550-8.
Dimopoulos MA, Kastritis E, Owen RG, Kyle RA, Landgren O, Morra E, et al. Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. Blood 2014; 124: 1404-11.